Sentinel lymph node biopsy in breast cancer

American Surgeon

Volumn 66, Issue 7, 2000, Pages 667-674

  Sakorafas, George H ^a,b   Tsiotou, Adelais G ^a  

^a IASO GENERAL HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DYE;

ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MEDICAL DECISION MAKING; PROGNOSIS; SENTINEL LYMPH NODE; TREATMENT FAILURE;

AXILLA; BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS;

EID: 0033949546     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Senofsky GM, Moffat FL Jr, Davis K, et al. Total axillary lympadenectomy in the management of breast cancer. Arch Surg 1991:126:1336-42.
2. Moffat FL Jr, Senofsky GM, Davis K, et al. Axillary node dissection for early breast cancer. Some is good, but all is better. J Surg Oncol 1992;51:8-13.
3. Fentiman IS, Mansel RE. The axilla: Not a no-go zone. Lancet 1991:337:221-3.
4. Gaglia P, Bussone R, Caldarola B, et al. The correlation between the spread of métastases by level in the axillary nodes and disease-free survival in breast cancer: A multifactorial analysis. Eur J Cancer Clin Oncol 1987:23:849-54.
5. Lee YT, Chan LS. Surgical treatment of carcinoma of the breast II. Prognostic factors influencing relapse rate. J Surg Oncol 1984:25:102-8.
6. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with promary breast cancer; An NSABP update. Cancer 1983;52:1551-7.
7. Lin PP, Allison DC, Wainstock J. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993;ll:1536-44.
8. Vencht CJ, Van de Brand HJ, Wajer DJM. Post-axillary dissection pain in breast cancer due to a lesion of the intercostobranchial nerve. Pain 1989;38:171-6.
9. Larson D, Weinstein M, Goldberg I. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiât Oncol Biol Phys 1985:12:1575-82.
10. Cascinelli N, Greco M, Bufalino R, et al. Prognosis of breast cancer with axillary node métastases after surgical treatment only. Eur J Cancer Clin Oncol 1987;23:795-9.
11. Nogushi M, Taniya T, de Aretxabala X, et al. The significance of regional lymph node dissection in the surgical management of breast cancer. Jpji J Surg 1989;19:21-8.
12. Morton DL, Wen DR, Wong JH. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
13. Krag DN, Meijer S, Weaver DL. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995;130:654-8.
14. Alazraki NP, Eshima D, Eshima LA, et al. Lymphoscintigraphy, the sentinel node concept and the intraoperative gamma probe in melanoma, breast cancer and other potential cancers. Semin Nucl Med 1997;27:55-67.
15. Bannister LH. Integumental system: Skin and breasts. In: Williams PL, Bannister LH, Berry MM, et al., eds. Gray's Anatomy, 38th Ed. New York: Churchill Livingstone, 1995, pp 375124.
16. Pickren JW. Lymph node métastases in carcinoma of the female mammary gland. Bull Roswell Park Mem Inst 1956;!: 79-85.
17. Berg JW. The significance of axillary node levels in the study of breast carcinoma. Cancer 1955;8:776-80.
18. Danforth D Jr, Findlay P, McDonald H, et al. Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J Clin Oncol 1986;4:655-62.
19. Veronesi U, Luini A, Gamimberti V, et al. Extent of metastatis axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 1990:16:127-33.
20. Sakorafas GH, Parley DR, Tsiotos GR. Conservative Surgery in Breast Cancer (Monograph). Athens, Greece: Lagos Medical Publications, 2000, In Press.
21. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995:222:394-401.
22. Kinne DW. Controversies in primary breast cancer management. Am J Surg 1993; 166:502-8.
23. Veronesi U, Luini A, Galimberti S, et al. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 1990:16:127-33.
24. Americal Joint Committee on Cancer. Manual for Staging of Cancer, 4th Ed. Philadelphia: J. B. Lippincott, 1993.
25. Sacre RA. Clinical evaluation of axillar lymph nodes compared to surgical and pathological findings. Eur J Surg Oncol 1986:12:169-73.
26. Fisher B, Wolmark N, Bauré M, et al. The accuracy of clinical nodal staging and of limited axillary dissection as a deter-minant of histologie nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981;152:765-72.
27. Noguchi M, Ohta N, Thomas M, et al. Clinical and biological prediction of axillary and internal mammary lymph node mé tastases in breast cancer. Surg Oncol 1993;2:51-8.
28. Noguchi M, Katev N, Miyazaki I. Diagnosis of axillary lymph node métastases in patients with breast cancer. Breast Cancer Res Treat 1996;40:283-93.
29. Pamilo M, Soiva M, Lavast EM. Real-time ultrasound, axillary mammography, and clinical examination in the detection of axillary lymph node métastases in breast cancer patients. J Ultrasound Med 1989;8:115-20.
30. Sacre R. Modem thoughts on lymph nodes in breast cancer. Semin Surg Oncol 1989;5:118-25.
31. Coopmans de Yoldi OF, Andreoli C, Costa A, et al. Lack of efficiency of xeroradiography to preoperatively detect axillary lymph node métastases in breast cancer. Breast Cancer Res Treat 1983;3:373-6.
32. Mustonen P, Farin P, Kosunen O. Ultrasonographic detection of metastatic axillary lymph nodes in breast cancer. Ann Chir Gynaecol 1990;79:15-8.
33. Täte JJT, Lewis V, Archer T, et al. Ultrasound detection of axillary lymph node métastases in breast cancer. Eur J Surg Oncol 1989:15:139-41.
34. Walsh JS, Dixon JM, Chetty U, Paterson D. Colour Doppler studies of axillary node métastases in breast carcinoma. Clin Radiol 1994;49:189-91.
35. March DE, Wechler RJ, Kurtz AB, Needleman L. CTpathologic correlation of axillary lymph nodes in breast carcinoma. J Comput Assist Tomogr 1991:15:440-4.
36. Allan SM, McVicar D, Sacks NPM. Prospects for axillary staging in breast cancer by magnetic resonance imaging. Br J Radiol 1993;66 (Suppl):15-6.
37. Tolmos J, Khalkhali I, Vargas H, et al. Detection of axillary lymph node metastasis of breast carcinoma with technitium-99m sestamibi scintimammography. Am Surg 1997:63:850-3.
38. Bombardieri E, Crippa F, Maffioli L, et al. Nuclear approaches for detection of axillary lymph node métastases. Q J Nucl Med 1998:42:54-65.
39. Smith 1C, Ogston KN, Whitfod P, et al. Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxo-D-glucose. Ann Surg 1998;228:220-7.
40. Sakorafas GH. Breast Cancer (Monograph). Athens, Greece: Lagos Medical Publications, 1999.
41. Sakorafas GH, Tsiotou AG. Breast Cancer Surgery. Historical evolution, current status, and future perspectives. Acta Oncol (In press).
42. Winchester DP, Cox JD. Standards for diagnosis and management of invasive breast carcinoma. CA Cancer J Clin 1998;48: 83-107.
43. Barnwell JM, Arredondo MA, Kollmorgen D, et al. Sentinel node biopsy in breast cancer. Ann Surg Oncol 1998;5:126-30.
44. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995:222:394-401.
45. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15: 2345-50.
46. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical re-section and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:3350.
47. Veronesi U, Paganelli G, Galimberti V. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative nodes. Lancet 1997;349:1864-7.
48. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel lymph node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
49. Borgstein PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph-node in breast cancer. Lancet 1997;349: 1668-9.
50. Statman R, Giuliano AE. The role of the sentinel lymph node in the management of patients with breast cancer. Adv Surg 1997;30:209-21.
51. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-8.
52. Cox CE, Pendas S, Cox JM, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998;227:645-53.
53. O'Hea BJ, Hill AD, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: Initial experience at Memorial SloanKettering Cancer Center. J Am Coll Surg 1998;186:423-7.
54. Uren RF, Giles-Howman RB, Thompson JF, et al. Mammary lymphoscintigraphy in breast cancer. J Nucl Med 1995;36: 1775-80.
55. Gulec SA, Moffat FL, Carroll RG, Krag DN. Gamma probe guided sentinel node biopsy in breast cancer. Q J Nucl Med 1997; 41:251-61.
56. Offodile R, Höh C, Barsky SH, et al. Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabeled dextran. Cancer 1998;82:1704-8.
57. Kingsley VB, Peters GN, Cheek JH. What constitutes adequate study of axillary lymph nodes in breast cancer? Ann Surg 1985;201:311-t.
58. Ludwig Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
59. Bettelheim R, Price KN, Gelber RD. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
60. Friedman S, Bertin F, Mouriesse H, et al. Importance of tumor cells in axillary node sinus margins ("clandestine" métastases) discovered by serial sectioning in operable breast carcinoma. Acta Oncol 1988;27:483-7.
61. Wells CA, Heryet A, Brochier J, et al. The immunohistochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984;50:193-7.
62. Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult métastases in node-negative breast cancer. Br J Cancer 1993;80:459-63.
63. De Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: réévaluation with longer follow-up. Br J Cancer 1992;66:523-7.
64. Chen Z-L, Wen D-R, Coulson WF. Occult métastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologie examination and conventional histology. Dis Markers 1991;9:239-48.
65. Nasser IA, Lee AKC, Bosari S, et al. Occult axillary lymph node métastases in "node-negative" breast carcinoma. Hum Pathol ' 1993;24:950-7.
66. Noguchi S, Aihara T, Nakamori S, et al. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 1994;74:1595-600.
67. Chassin JL. Axillary lymphadenectomy. In: Chassin JL. Operative Strategy in General Surgery. New York: Springer Verlag, 1994, pp 468-72.
68. Sakorafas GH, Tsiotou AG. Axillary lymph node dissection in breast cancer: Current status and controversies, alternative strategies, and future perspectives. Acta Oncol (In press).
69. Borgstein PJ, Pijpers R, Comans EF, et al. Sentinel lymph node biopsy in breast cancer: Guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998; 186:275-83.
70. Clayton F, Hopkins CL. Pathologic correlates of prognosis in lymph node-positive breast carcinoma. Cancer 1993;7I: 1780-90.
71. Noguchi S, Aihara T, Motomura K, et al. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Am J Pathol 1996;2:649-56.
72. Ollila DW, Brennan MB, Guiliano AE. Therapeutic effect of sentinel lymphadenectomy in Tl breast cancer. Arch Surg 1998; 133:647-51.
73. McLean RG, Ege GN. Prognostic value of axillary lymphoscintigraphy in breast cancer patients. J Nucl Med 1986;27: 1116-24.
74. Kramer EL. Lymphoscintigraphy: Radiopharmaceutical selection and methods. Nucl Med Biol 1990; 17:57-63.
75. Noguchi M, Nagayoshi O, Koyasaki N, et al. Re-appraisal of internal mammary node métastases as a prognostic factor in patients with breast cancer. Cancer 1991;68:1918-24.
76. Veronesi U, Cascinelli N, Greco M, et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985;202:702-7.
77. Morrow M, Foster RS. Staging of breast cancer. Arch Surg 1981;! 16:748-51.
78. Holdsworth PJ, Hopkinson JM, Leveson SH. Benign axillary epithelial lymph node inclusions: A histological pitfall. Histopathology 1988;13:226-8.
79. Dbglioni C, Dell'Orto P, Zanetti G, et al. Cytokeratinimmunoreactive cells of human lymph nodes and spleen in normal and pathological conditions: An immunohistochemical study. Virch Arch A Pathol Anat Histopathol 1990;416:479-90.
80. Bergqvist L, Strand S-E, Persson BRR. Particle sizing and biokinetics of interstitial lymphoscintigraphic agents. Semin Nucl Med 1983;13:9-19. .
81. Gukec SA, Moffat FL, Carrol RG. The expanding clinical role for intraoperative gamma probes. In: Freeman LM, ed. Nuclear Medicine Annual. Philadelphia: Lippincott-Raven, 1997, pp 209-37.
82. Goldhirsch A, Click JH, Gelber RD, Senn H-J. Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998;90:1601-8.
83. Koller M, Barsuk D, Zippel D, et al. Sentinel lymph node involvement: A predictor for axillary node status with breast cancer: Has the time come? Eur J Surg Oncol 1998;24:166-8.
84. Crossin JA, Johnson AC, Stewart PB, Turner WW. y-Probe-guided reaction of the sentinel lymph node in breast cancer. Am Surg 1998;64:666-8.